Antiviral Molnupiravir STELLA 400 mg with GONSA distributed QR code on packaging

As of June 2022, the B.1.1.529 variant (Omicron) of SAR.S-CoV-2 has been divided into five distinct sublineages: BA.1, BA.2, BA.3, BA .4, and BA.5.1. Most of the pathogenic Omicron variants belong to the BA.2 sublineage. Currently, however, the BA.2.12.1 subvariant of BA.2 and the BA.4, and BA.5 variants are increasing rapidly in some regions of the world. These variants are all capable of causing disease in people who have tested positive for COVID-19, and even those who have gotten enough vaccine boosters.

According to a study published in the NEJM journal, molnupiravir was tested on the new variant by determining an in vitro 50% inhibitory concentration (IC50) against BA.2.12.1, BA.4 and BA. 5. The test has shown that molnupiravir is one of the three antiviral agents including molnupiravir, remdesivir, nirmatrelvir that has therapeutic value against the prevalent subvariants BA.2.12.1, BA.4 and BA. 5. According to the study, molnupiravir remains almost equally effective against the new mutations compared to its effect against previous variants.

In Vietnam, currently, there are three domestic companies that are able to actively produce medicines containing the active agent molnupiravir, and GONSA is very proud to be the Official Distributor of Molnupiravir Stella 400 mg. With this mission, GONSA is committed to always ensuring that the distribution fulfills the needs of society.

Molnupiravir distributed nationwide by GONSA at pharmacies

However, molnupiravir is only suitable for use in COVID-19 patients who are 18 years or older with mild to moderate symptoms and at least one risk factor for severe disease progression. In addition, we still need to fully comply with the treatment instructions of the medicine to make it work best, limit unwanted effects and help patients recover quickly.

Find more information about Molnupiravir here:
Source of NEJM journal:
Call center for order consultation: 1800 646899
Call center for professional consultation: 1800 1248